YAbS







ELA026 Clinical TBD

Antibody Information

Entry ID 595
INN None
Status Clinical
Drug code(s) ELA026
Brand name None
mAb sequence source mAb human
General Molecular Category TBD
Format, general category TBD
Format details TBD
Isotype (Fc) IgG1
Light chain isotype TBD
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) SIRP alpha
Indications of clinical studies Secondary Hemophagocytic Lymphohistiocytosis
Primary therapeutic area Immune-mediated / inflammatory disorders

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Phase 2/3
Status Active
Start of clinical phase (IND filing or first Phase 1) October 15, 2021
Start of Phase 2 May 19, 2022
Start of Phase 3
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Electra Therapeutics Inc.
Licensee/Partner None
Comments about company or candidate
NCT05416307 Phase 1 study started in May 2023 converted to a Phase 2/3 study in Mar 2025.
NCT05556863 Phase 1 study started in Oct 2021.
Full address of company 201 Haskins Way, 5th Floor South San Francisco, CA 94080
North America
United States of America
https://electra-therapeutics.com/

Description/comment

ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation.

Additional information

Anticipated events None
Factor(s) contributing to discontinuation None